立他司特 T3977

Product Introduction
Bioactivity


英文名: Lifitegrast

描述: Lifitegrast (SAR 1118) 是一种整合素淋巴细胞功能相关抗原 1 拮抗剂， 抑制 Jurkat T 细胞附着于ICAM-1的IC50为 2.98 nM。

体外活性: Lifitegrast is a novel small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus lessening overall inflammatory responses. Lifitegrast strongly inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM[1].

体内活性: Lifitegrast, has potent anti-inflammatory activity on corneal inflammation induced by antibiotic-killed P. aeruginosa and S. aureus in the presence of a silicone hydrogel lens with the optimal application being a 1% solution applied either 2 or 3 times prior. Topical application of lifitegrast to the corneal surface of healthy adults is safe and well tolerated[2]. SAR 1118 ophthalmic drops administered thrice daily deliver therapeutic levels of SAR 1118 in the retina and can alleviate the retinal complications associated with diabetes[3].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (81.24 mM)


关键字: ICAM-1 | T cell | inhibit | SHP606 | SHP 606 | dry eye disease | SAR-1118 | Jurkat T | LFA-1 | Lifitegrast | Integrin | SAR1118 | inflammatory cycle | Inhibitor

相关产品: Cyclo(RGDyK) trifluoroacetate | A-286982 | Tirofiban | αvβ1 integrin-IN-1 | Arg-Gly-Asp-Ser acetate | α2β1 Integrin Ligand Peptide acetate | LXW7 TFA (1313004-77-1 free base) | Cucurbitacin B | PLN-1474 | Egaptivon pegol

相关库: Drug Repurposing Compound Library | Approved Drug Library | ReFRAME Related Library | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compounds Library Max | Human Metabolite Library | Inhibitor Library | NO PAINS Compound Library | Nonsteroidal Anti-Inflammatory Compound Library | Bioactive Compound Library

立他司特 T3977信息由TargetMol中国为您提供，如您想了解更多关于立他司特 T3977报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途